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Activation of phospholipase D by growth factors and oncogenes in murine
fibroblasts follow alternative but cross-talking pathways
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Instituto de Investigaciones Biome! dicas, CSIC, Arturo Duperier 4, 28029 Madrid, Spain
Phospholipase D (PLD) is activated by a variety of stimuli,
including mitogenic stimulation by growth factors and oncogene
transformation. Activation of PLD by growth factors requires
protein kinase C (PKC) since depletion of the enzyme by down-
regulation or direct inhibition by specific drugs completely
abrogates this effect. Transformation by the ras and src oncogenes
is also associatedwith an increase in basal PLDactivity.However,
this effect is not dependent on PKC, suggesting that growth
factors and oncogenes may activate PLD by two independent
mechanisms. Here we demonstrate that activation of PLD by
phorbol esters is greatly enhanced in ras-transformed cells,
suggesting synergistic activation of PLD by ras oncogenes and
PKC. Also, ras-transformed cells showed a dramatic attenuation
of the PLD activation induced by growth factors, although
receptor function was still detectable. This attenuation paralleled
the specific uncoupling of the phosphatidylinositol-specific
INTRODUCTION
Several lines of evidence implicate the involvement of
phospholipase D (PLD) in signal-transduction processes in a
variety of cellular systems. Besides the overwhelming evidence
that growth factors activate PLD [1], it is well established that
PLD mediates signal-transduction processes such as the action of
gonadotrophin-releasing hormone on ovary cells [2] and granule
secretion in human neutrophils [3]. Also, a PLD activity is
involved in sporulation in Saccharomyces [4]. We have also
recently demonstrated that (1) maturation of Xenopus laeis
oocytes induced by microinjection of the activated Ras protein is
accompanied by activation of PLD [5], (2) germinal vesicle
breakdown induced by Ras proteins is inhibited by neomycin at
concentrations reported to be inhibitory for PLD and (3) PLD-
derived products mimic the biological effect of Ras proteins in
this system [5]. In addition, several reports demonstrate that
exogenously added PLD has mitogenic activity [6,7].
In support of a role for PLD in signal transduction, growth
factor stimulation of murine fibroblasts induces a rapid and
transient activation of PLD, which has been demonstrated to be
dependent on protein kinase C (PKC) by down-regulation of the
enzyme [8,9]. Overexpression of PKCa enhances PLD activation
by growth factors, further supporting the involvement of a
diacylglycerol (DAG)-sensitive PKC isoenzyme in this process
[10,11]. Although the precise mechanism for activation of PLD
Abbreviations used: PLCc, phospholipase Cc ; PLD, phospholipase D; PKC, protein kinase C; PI-PLC, phosphatidylinositol-specific phospholipase ;
PDGF, platelet-derived growth factor ; DAG, diacylglycerol ; IP3, inositol trisphosphate ; GTP[S], guanosine 5«-[c-thio]triphosphate ; PI3K,
phosphatidylinositol 3-kinase ; DMEM, Dulbecco’s modified Eagle’s medium; TGFa, transforming growth factor a ; PDBu, phorbol 12,13-dibutyrate ;
bFGF, basic fibroblast growth factor ; FCS, fetal calf serum; PtdBut, phosphatidylbutanol ; MAPK, mitogen-activated protein kinase ; IP, inositol
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phospholipase C (PI-PLC) pathway, indicating that activation of
PLD by growth factors may be mediated by PI-PLC and PKC
activation. Attenuation of PLD activation by platelet-derived
growth factor was also observed in several oncogene-transformed
cells, as well as the uncoupling of the PI-PLC pathway. Neither
the co-operation with PKC activation nor the attenuation of the
PLD response to growth factors in ras-transformed cells was a
general consequence of cell transformation, since cells trans-
formed by other oncogenes showed a normal response to either
treatment. These results support the existence of at least two
alternative signalling routes for the activation of PLD, one
mediated by the PI-PLC}diacylglycerol}PKC pathway and a
second one mediated by several oncogenes, independent of the
PKC pathway, which synergizes with the PI-PLC}PKC-de-
pendent pathway.
induced by growth factors is still not known, strong evidence
suggests that it is mediated by the activation of phospholipase Cc
(PLCc) that follows growth factor receptor activation [12,13].
Thus, on growth factor stimulation, PLCc becomes activated,
resulting in phosphatidylinositol (PI) hydrolysis and the gen-
eration of DAG and inositol trisphosphate (IP
$
). IP
$
is re-
sponsible for the opening of endoplasmic reticulum Ca#+ channels
and the increase in free cytosolic Ca#+. Since classical PKCs are
activated by DAG and Ca#+, PLCc may act as a link between
tyrosine kinase receptors and the PKC stimulation that leads to
PLD activation. In keeping with this hypothesis, activation of
GTPase-coupled receptors also induces activation of PLD
[12,13], which may be mediated by activation of the PI-PLCb
isoenzyme with the generation of DAG and IP
$
and the further
activation of PKC.
In addition to PI-PLC and PKC, some GTPases have also
been implicated in PLD activation. Treatment of membranes
isolated from several cell lines with the non-hydrolysable GTP
analogue, guanosine 5«-[c-thio]triphosphate (GTP[S]), results in
PLD activation. Several GTPases that belong to both the classical
G-protein family as well as the Ras superfamily have been
proposed as being responsible for this effect [1]. Whereas ADP
ribosylation factor has been shown to induce PLD activation in
membranes from HL-60 cells [14–16], the Rho protein is re-
sponsible for this effect in neutrophils and HL-60 cells [17–20].
Also Ras proteins have been implicated in the induction of PLD
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activation, since ras transformation is associated with increased
PLD activity in fibroblasts [6,21] as well as in Xenopus laeis
oocytes [5]. We have recently demonstrated that, like other well-
established Ras effectors such as Raf-1 and phosphatidylinositol
3-kinase (PI3K), stable ras-transformed cells do not always show
a constitutive activated PLD, suggesting that other factors may
be also involved in this activation [22].
It has been reported that, like ras-transformed fibroblasts, src-
transformed fibroblasts show constitutive elevated PLD activity
[23]. This effect is also observed in membranes isolated from src-
transformed cells and it is dependent on the addition of GTP[S],
suggesting that it is mediated by a GTPase [24]. It has been
suggested that this GTPase corresponds to the Ras protein, since
preincubation of membranes isolated from src-transformed cells
with the Ras-neutralizing monoclonal antibody Y13-259
abrogates PLD activation [25]. Furthermore PLD activation
induced by src involves not only Ras but also Ral, another
GTPase of the Ras superfamily, through the Ras-dependent
activation of Ral-GDS [21].
These results imply that, although PLD activation is a frequent
event associated with growth stimulation, our actual knowledge
of both the mechanism involved and its relevance remains very
scant. In this study, we have further investigated the mechanisms
involved in the regulation of PLD by growth factors and Ras
proteins. The results presented demonstrate the existence of at
least two alternative mechanisms for PLD activation, one of
them involving Ras proteins.
MATERIALS AND METHODS
Cell culture and reagents
Normal NIH 3T3 mouse fibroblasts as well as ras-transformed
derivatives were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% newborn calf serum (Gibco)
under standard conditions of temperature (37 °C), humidity
(95%) and CO
#
(5%). The ras-transformed cell lines used here
were obtained from independent transfections and have been
described previously [6,22], or were freshly generated using an
LTR-driven vector (LP14-8) or simian virus 40 early promoter
(710RAS) and present a transformed morphology as well as high
expression of exogenous Ras protein. Cell lines transformed by
transforming growth factor a (TGFa) (611-20), v-src (SRC),
c-sis (704-42), trk (C51-36), v-fgr (C26-41) and v-fms (C51-64)
were obtained from A. Cuadrado and S. A. Aaronson (The
Derald H. Ruttenberg Cancer Center, New York, NY, U.S.A.).
All ras-transformed cells and those transformed by the different
oncogenes were generated using the same parental NIH 3T3 cell
line. The cell line transformed by the met (12b) oncogene was
obtained from M. Park (McGill University, Montreal, Canada).
[2-$H]Glycerol (1 Ci}mmol) and [methyl-$H]thymidine (45 Ci}
mmol) were from Amersham, [U-"%C]glycerol (148 mCi}mmol)
was from Moravek Biochemicals, myo-[2-$H]inositol was from
Amersham (22±8 Ci}mmol) or NEN (15±2 Ci}mmol), and butan-
1-ol was from Merck. Bisindolylmaleimide was purchased from
Calbiochem. Phorbol 12,13-dibutyrate (PDBu) was purchased
from Sigma and platelet-derived growth factor (PDGF) and
basic fibroblast growth factor (bFGF) were from UBI.
Assay of PLD activity
Activation of PLD can be measured accurately by its trans-
phosphatidylating activity on butanol to generate phosphatidyl-
butanol (PtdBut) [23,26]. Cells were grown in six-well plates and
labelled for 48–72 h in the presence of 10 lCi}ml [2-$H]glycerol
(0±5–1 Ci}mmol) or 1 lCi}ml [U-"%C]glycerol. In some experi-
ments cells were labelled for 24 h in DMEM supplemented with
0±2% fetal calf serum (FCS). In down-regulation experiments,
350 nM PDBu was added to the culture medium during the
labelling period. To assay PLD activity, labelling medium was
discarded, and cells were washed with TD buffer (137 mM NaCl,
5 mM KCl, 1 mM Na
#
HPO
%
, 20 mM Tris}HCl, pH 7±4) and
incubated for 30–45 min in serum-free DMEM supplemented
with 0±5% butan-1-ol in the presence of the indicated agonists or
inhibitors. The cells were then scraped into 1 ml of methanol,
and plates washed once with 1 ml of methanol. The two methanol
samples were collected and mixed with 2±5 ml of chloroform and
1±25 ml of water. The organic phases were dried in a 37 °C
heating block under a nitrogen stream and the lipids separated
by TLC using silica gel 60A plates (Whatman; LK6D). The
plates were developed with the upper phase of a mixture of ethyl
acetate}iso-octane}acetic acid}water (90:50:20:100, by vol.)
plus 1 ml of acetic acid. They were then sprayed with enhancer
(Dupont) and exposed to X-ray-sensitive films. Bands corre-
sponding to PtdBut were scraped off and counted for radio-
activity. PtdBut was identified using a standard generated in
itro using purified PLD and ["%C]phosphatidylcholine as sub-
strate. Counts in PtdBut were normalized for the radioactivity
incorporated into total lipid. Where indicated, plates were
visualized and quantified using an electronic autoradiography
system (InstantImager ; Packard).
Determination of tyrosine phosphorylation and mitogen-activated
protein kinase (MAPK) activation
The experiments were performed using confluent cells that had
been serum-starved for 12–24 h. The medium was replaced with
serum-free DMEM containing the indicated amounts of PDGF-
BB (human recombinant). Stimulation proceeded at 37 °C for
5–10 min, and was terminated by aspirating off the medium,
washing twice with ice-cold TD buffer and adding 300 ll of ice-
cold lysis buffer (50 mM Tris}HCl, pH 7±4, 0±25% Nonidet P40,
0±25% SDS, 150 mM NaCl, 15 mM 2-glycerophosphate, 10 mM
sodium pyrophosphate, 50 mM NaF, 10 lg}ml aprotinin, 1 mM
PMSF) or RIPA buffer (50 mM Tris}HCl, pH 7±4, 150 mM
NaCl, 0±5% Nonidet P40, 0±5% deoxycholate, 0±1% SDS,
15 mM 2-glycerophosphate, 10 mM sodium pyrophosphate,
50 mM NaF, 10 lg}ml aprotinin, 1 mM PMSF). Nuclei and
detergent-insoluble material were removed by centrifugation at
11000 g (13000 rev.}min) in a Microfuge for 20 min. The result-
ing supernatants were assayed for total cell protein (Bio-Rad),
and equal amounts of cell lysates (30–100 lg) were boiled at
95 °C for 5 min in SDS}PAGE sample buffer. For Western-blot
analysis, proteins were subjected to SDS}PAGE (8% gels for
phosphotyrosine analysis and 10% gels for MAPK analysis
poured on 20 cm¬20 cm glass plates). Resolved proteins were
transferred to nitrocellulose, and blots were blocked for 1 h in
3% non-fat dried milk in T-TBS (20 mM Tris}HCl, pH 7±5,
150 mM NaCl, 0±05% Tween 20) plus phosphotyrosine phos-
phatase inhibitors (15 mM 2-glycerophosphate, 10 mM sodium
pyrophosphate, 50 mM NaF) for the anti-phosphotyrosine
Western blots. Blots were washed once in T-TBS and incubated
for 2 h with an anti-phosphotyrosine-specific monoclonal anti-
body (RPN 138; Amersham) or a polyclonal serum raised
against a C-terminal peptide of MAPK and developed by
enhanced chemiluminescence (Amersham).
Analysis of PI3K activity
Cells were serum-starved overnight and stimulated with 10
ng}ml PDGF for 5 min. They were then washed with cold PBS,
rinsed with buffer A (137 mM NaCl, 20 mM Tris}HCl, pH 8,
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Figure 1 PDGF activates PLD in a PKC-dependent manner that is additive with PDBu treatment
(a) NIH 3T3 cells were grown and labelled with 1 lCi/ml [14C]glycerol in DMEM supplemented with 10% newborn calf serum for 48 h. Where indicated, cells were pretreated with 350 nM PDBu
during the labelling period. After labelling, cells were washed and incubated for 30 min in serum-free DMEM alone or supplemented with 8 lM bisindolylmaleimide (Bisindol). Then cells were
stimulated with PDGF (20 ng/ml) or PDBu (350 nM) for 20–30 min and processed as indicated in the Materials and methods section for PLD activation using an electronic autoradiography system
(InstantImager). Data represent means³variation for duplicate determinations. The experiment shown is a representative of four (down-regulation) or two (bisindolylmaleimide) with similar results.
(b–d) NIH 3T3 cells were grown and labelled as indicated above and then washed and stimulated for 30 min in serum-free DMEM supplemented with the indicated amounts of PDGF (b) or PDBu
(c) to saturation. The effect of a combination of the two treatments, PDGF (33 or 100 ng/ml) alone or plus PDBu (350 nM), is shown in (d). Both the observed experimental results (black bars)
and those expected for the additional independent treatment with 350 nM PDBu plus either 33 ng/ml (*) or 100 ng/ml PDGF (**) are shown. Data are means³variation for duplicate determinations
quantified by an electronic autoradiography system. The experiment shown is representative of at least three independent experiments.
1 mM MgCl, 1 mM CaCl
#
), and lysed in buffer containing 1%
Nonidet P40 and 1 mM PMSF at 4 °C for 20 min. Insoluble
material was removed by centrifugation. The supernatants (1 ml)
were incubated with a mouse monclonal anti-phosphotyrosine
antibody overnight at 4 °C. Equivalent amounts of Protein
A–Sepharose CL4B (Sigma) were added, and incubation was
continued for an additional hour. The immunoprecipitates were
collected and washed once with PBS, twice with 0±5 M LiCl}
0±1 M Tris}HCl, pH 7±4, and finally with 10 mM Tris}100 mM
NaCl}1 mM EDTA. Immunoprecipitates were then assayed for
PI phosphorylation activity, as described by Varticovski et al.
[27].
Analysis of PI-PLC activity
Cells were grown in six-well plates in DMEM supplemented with
10% newborn calf serum and labelled with 50 lCi}ml myo-
[2-$H]inositol for 48–72 h. After being radiolabelled, cultures
were washed with TD buffer, and cells were incubated for
15–20 min in serum-free medium in the presence of 22 mM LiCl.
Where indicated, cells were stimulated with mitogens in the
presence of 22 mM LiCl. Culture media were discarded and
reactions were terminated by the addition of 0±8 ml of ice-cold
5% HClO
%
. Wells were kept at 4 °C for 15–20 min, then the
HClO
%
fractions were collected and the wells washed with an
additional 1 ml of water. HClO
%
and water washes were diluted
to a final volume of 5 ml with water, and total inositol phosphates
(IPs) were eluted from Dowex 1 (X8) columns with 1±2 M
ammonium formate}0±1 M formic acid as described previously
[12]. The resulting counts were normalized for the radioactivity
content in the HClO
%
insoluble material.
Growth in soft agar
Equivalent numbers of cells from each cell line were plated in
duplicate in 60 mm dishes. Either 5¬10$ or 20¬10$ cells in
0±5 ml were mixed with 1±5 ml of DMEM­Hepes supplemented
with 10% FCS and 0±5% noble agar warmed at 42 °C. The
mixture was then plated on a layer of DMEM­Hepes supple-
mented with 10% FCS and 0±5% noble agar. Once a week
500 ll of DMEM supplemented with 10% FCS was added to
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each dish. Colonies were photographed and quantified 2–3 weeks
after plating.
Mitogenic assays
Cells were seeded on 24-well plates and grown to confluence,
serum-starved for 24 h in 0±2% newborn calf serum and then
stimulated for an additional 24 h with the indicated mitogens.
During the last 6 h, 1 lCi}ml [methyl-$H]thymidine (45 Ci}
mmol; Amersham) was added and cells were incubated under
standard conditions of temperature, humidity and CO
#
atmos-
phere. [$H]Thymidine incorporation into DNA was determined
as the amount of radioactivity present in trichloroacetic acid-
insoluble material. The cells were rinsed twice with PBS and
twice with ice-cold 16% trichloroacetate. Then trichloroacetate-
insoluble material was solubilized in 1 ml of 0±25 M NaOH for
1 h. The solubilized solution was scintillation counted.
RESULTS
Growth factors activate PLD in a PKC-dependent manner that is
additive with PDBu treatment
Suppression of PKC by either down-regulation by chronic
treatment with PDBu or direct inhibition with bisindolyl-
maleimide completely abrogates PLD activation by growth
factors such as PDGF or bFGF in NIH 3T3 cells (Figure 1a).
These results are consistent with previous observations by other
investigators using other cell systems such as Swiss 3T3 cells [9].
Thus mitogenic stimulation of NIH 3T3 fibroblasts with growth
factors is associated with a PKC-dependent activation of PLD.
The addition of PDGF or PDBu to NIH 3T3 cells induced a
dose-dependent activation of PLD with saturation at 30 ng}ml
for PDGF (Figure 1b) and 350 nM for PDBu (Figure 1c).
Furthermore treatment of cells with saturating concentrations of
PDGF and PDBu at the same time caused an additive effect on
PLD activity when compared with PLD stimulation by each
agonist alone (Figure 1d), since the increase in PLD activity
matched that of the addition of each independent treatment
(Figure 1d). These results are in agreement with the hypothesis
that activation of PLD induced by growth factors is mediated, at
least in part, by activation of PI-PLC through the production of
DAG and Ca#+, resulting in the subsequent activation of PKC
[12,13]. However, this seems not to be the only mechanism for
activation of PLD, since there is still some co-operation when
both growth factors and phorbol esters are added together.
These results are in keeping with those recently reported by Kim
and colleagues and others showing that growth factors can
induce activation of PLD by a mechanism that may be in-
dependent of PI-PLC [28–30].
ras transformation synergizes with PKC stimulation of PLD
activation
When ras-transformed NIH 3T3 cells were stimulated with
PDBu, PLD activity was synergistically enhanced as compared
with PLD activation induced by PDBu in control cells (Figure 2).
PKC down-regulation by chronic treatment with PDBu com-
pletely eliminated the stimulation of PLD by PDBu in both ras-
transformed and control cells. Thus the co-operative effects of
ras and PDBu on PLD activity were mediated by PKC. A similar
result was obtained by direct inhibition of PKC by bisindolyl-
maleimide, a specific inhibitor of the PKC family (results not
shown; [22]).
As we have previously reported, some of the ras-transformed
cells show a constitutive elevated PLD activity [22]. The above
0.06
0.05
0.04
0.03
0.02
0.01
0
P
td
B
u
t/t
o
ta
l l
ip
id
No pretreatment
PKC down-regulation
...
Figure 2 Ras co-operates with PKC in PLD activation
Cells were grown to confluence and then serum-starved and labelled with [3H]glycerol as
described in the Materials and methods section. Where indicated, PKC was down-regulated by
chronic treatment with 350 nM PDBu during the labelling period. The cells were then washed
and stimulated (­) with 350 nM PDBu for 35 min or left untreated (®). Data represent
means³variation for duplicate determinations. Cell lines used correspond to normal NIH 3T3
cells (Control) and the LP8-3A cell line (Ras) generated as previously described [22]. The
experiment was repeated five times with similar results, using either the LP8-3A cell line or
distinct ras-transformed cell lines (H-rasV12 as well as v-K-ras) generated as previously
described [22].
effect of co-operative activation by PDBu and ras was observed
in all the ras-transformed NIH 3T3 cell lines analysed, regardless
of the constitutive increase in PLD activity (Table 1). This PLD
activation induced by PDBu was significantly different in all
ras-transformed cells from that induced in control cells when
analysed by Student’s t test (P% 0±001; n¯ 15).
Attenuation of growth-factor-induced PLD activation by ras
transformation
As indicated above, growth factors activate PLD by a PKC-
dependent mechanism, which probably implies activation of PI-
PLC and generation of the PKC-activating molecules, DAG and
Ca#+. This process is mediated by the activation of the PI-specific
PLCc after stimulation of the receptor. Figure 2 shows that ras
co-operates synergistically with PKC stimulation by PDBu
treatment in PLD activation. In contrast, as shown above (Figure
1), growth factors do not co-operate synergistically with PKC in
PLD activation but instead have an additive effect. Thus we next
investigated if growth factor stimulation, which is able to activate
PKC, co-operated synergistically or additively with ras in PLD
activation. As shown in Table 2, the PLD response to PDGF-BB
and bFGF treatment was much lower (or even abolished) in the
ras-transformed cells than in normal NIH 3T3 cells. This result
implies that growth factors and ras do not co-operate in PLD
activation, but rather ras transformation attenuates the
PLDresponse inducedby growth factors.Attenuationof the PLD
response was highly significant when analysed by Student’s t test
for PDGF (P% 0±001; n¯ 15) and FGF (P¯ 0±036; n¯ 4).
In order to identify themechanism bywhich ras transformation
abrogated the activation of PLD by growth factors, we studied
whether receptor function was affected in ras-transformed cells
by investigating receptor autophosphorylation or activation of
PI3K, one of the best characterized substrates for the PDGF
receptor. Neither receptor autophosphorylation (Figure 3a) nor
receptor activity towards endogenous substrates such as PI3K
(Figure 3b) were significantly affected in the ras-transformed
cells, an indication that the effect on PLD activation was quite
specific. Furthermore activation of the MAPK pathway was also
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Table 1 Synergistic effect of PDBu and ras transformation on PLD activity
Cells were grown under standard conditions and, when confluent, serum-starved in DMEM
supplemented with 0±2% newborn calf serum and labelled for 24 h in the presence of
10 lCi/ml [2-3H]glycerol. To assay PLD activity, labelling medium was discarded, cells were
washed with TD buffer and incubated for 30 or 45 min in DMEM supplemented with 0±2%
newborn calf serum and 0±5% butan-1-ol in the presence or absence of 350 nM PDBu. PLD
activity was quantified as described in the Materials and methods section. Data represent the
mean³variation for duplicate determinations. Fold increase represents the ratio between the
PDBu-treated cells and the untreated controll cells. Net increase is the data for the PDBu-treated
cells minus the background levels in untreated control cells.
PtdBut/total lipid
Expt. Fold Net
no. Cell line Gene Control ­PDBu increase increase
1 NIH 3T3 None 3±92³0±53 26±72³2±16 6±81 22±80
H-ras H-rasV12 6±85³0±73 96±77³1±52 14±12 89±92
2 NIH 3T3 None 3±03³1±34 16±77³0±22 5±53 13±74
K2 v-K-ras 6±34³0±49 80±23³0±07 12±65 73±89
3 NIH 3T3 None 3±39³0±88 25±06³0±06 7±39 21±67
710RAS H-rasV12 2±14³0±18 55±48³6±96 25±88 53±34
4 NIH 3T3 None 3±89³0±20 35±66³1±24 9±15 31±77
LP8-1 None 4±27³0±52 36±47³0±92 8±53 32±20
LP8-3 H-rasV12 3±74³0±46 59±73³2±67 15±96 55±99
observed in ras-transformed cells after stimulation with specific
growth factors such as PDGF or bFGF, a further indication of
the conservation of an intact signalling cascade in the ras-
transformed cells even though, in some of the cell lines, a partial
activation of MAPK by ras transformation could be observed
(Figure 3c). Finally, analysis of [$H]thymidine uptake in response
to PDGF or bFGF stimulation showed the same maximum level
in both normal and ras-transformed cells besides the higher basal
level of the ras-transformed cells (Figure 3d). These results
further strengthen the conclusion that the mitogenic signalling
for PDGF and FGF is functional alongside ras transformation.
We also tested whether ras transformation affected the gen-
eration of PI-derived metabolites in response to growth factors
as an indication of PI-PLC activation. To this end, cells were
Table 2 Attenuation of the growth-factor-induced PLD activity in ras transformed cell lines
Cells were grown under standard conditions and, when confluent, serum-starved in DMEM supplemented with 0±2% newborn calf serum and labelled for 24 h in the presence of 10 lCi/ml
[2-3H]glycerol. To assay PLD activity, labelling medium was discarded, cells were washed with TD buffer and incubated for 30 or 45 min in DMEM supplemented with 0±2% newborn calf serum
and 0±05% butan-1-ol in the presence or absence of 10 ng/ml PDGF-BB or bFGF. PLD activity was quantified as described in the Materials and methods section. Data represent the mean³variation
for duplicate determinations. Fold increase represents the ratio between the PDGF- or FGF-treated cells and the untreated control cells. Net increase is the data for the PDGF- or FGF-treated cells
minus the background levels in the untreated control cells. ND, not determined.
PtdBut/total lipid Fold increase Net increase
Expt. no. Cell line Gene Control ­PDGF ­bFGF ­PDGF ­bFGF ­PDGF ­bFGF
1 NIH 3T3 None 8±59³3±69 20±95³3±95 ND 2±43 ND 12±36 ND
H-ras H-rasV12 11±78³0±87 14±19³1±08 ND 1±20 ND 2±41 ND
2 NIH 3T3 None 3±39³0±88 16±15³0±40 ND 4±76 ND 12±76 ND
710RAS H-rasV12 2±14³0±18 5±40³0±71 ND 2±51 ND 3±26 ND
3 NIH 3T3 None 6±12³0±82 14±67³0±92 10±99³0±57 2±39 1±79 8±55 4±87
LP8-3A H-rasV12 6±26³0±63 7±43³0±43 7±29³0±61 1±18 1±16 1±17 1±03
H-ras H-rasV12 10±81³0±12 14±28³1±33 13±97³0±15 1±32 1±29 3±47 3±16
4 LP8-1 None 4±14³1±18 9±74³0±00 7±79³0±42 2±35 1±88 5±60 3±65
LP8-3 H-rasV12 5±02³0±03 6±46³0±82 7±88³0±01 1±28 1±57 1±44 2±86
H-ras H-rasV12 14±66³0±75 14±39³0±95 14±33³0±41 0±98 0±97 ®0±27 ®0±33
labelled with myo-[$H]inositol and then stimulated with PDGF-
BB, bFGF or serum, and the release of total IPs was quantified.
As shown in Figure 4, cells transformed by the ras oncogene lost
their ability to generate PI-derived metabolites in response to
growth factors such as PDGF or bFGF or even 20% FCS. A
similar attenuation of PI-PLC activation in response to PDGF
was observed in other ras-transformed cell lines (Table 3), an
indication that this effect is not dependent on any specific ras
clone. All of these results indicate that ras transformation
specifically affects the pathway by which growth factors induce
PLD activation, probably by abrogating the activation of PI-
PLC, but has no detectable effect on other functions triggered by
receptor activation.
Not all transformed cells show co-operation with PDBu or PDGF
attenuation in the PLD response
We next determined whether the synergism between ras and
PDBu in PLD activation and the attenuation of PLD activation
induced by PDGF resulted from a non-specific effect resulting
from cell transformation. To this end, we studied the induction
of PLD activity by PDBu and PDGF treatment in a number of
cell lines transformed by oncogenes other than ras. NIH 3T3
cells transformed by the c-sis, v-fgr, v-fms, trk, v-src and v-met
oncogenes as well as those transformed by TGFa were investi-
gated. The transforming capacity of each cell line was taken as its
ability to grow in soft agar and compared in relative terms
among the different cell lines (Table 4). Thus cells overexpressing
TGFa showed weak transforming activity in this assay, whereas
those expressing the trk or c-sis oncogenes were moderately
transforming, those expressing the v-fgr or v-fms oncogenes were
highly transforming, and those expressing the v-met, v-src or ras
oncogenes were very highly transforming.
As shown in Table 4, there is no correlation between cell
transformation and synergism in PLD stimulation with PKC
activation by PDBu, since the cells transformed by oncogenes
such as trk, v-fgr or v-fms, which showed moderate to high
transforming activity, and those transformed by TGFa, which
showed weak transforming activity, responded to PDBu treat-
ment with a similar level of PLD activation to control untrans-
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Figure 3 Lack of effect on PDGF receptor by ras-induced transformation
(a) Western blot using an anti-phoshotyrosine (aP-Tyr) antibody. Cells were grown to confluence, serum-starved for 20 h and then stimulated with 20 ng/ml PDGF-BB (­) for 10 min or left untreated
(®). After incubation, cells were lysed, and equivalent amounts of cell extracts (100 lg) resolved by SDS/PAGE, transferred to nitrocellulose paper and blotted against an aP-Tyr antibody as
described in the Materials and methods section. Molecular-mass markers used as standards are indicated. Control cells correspond to the LP8-1 cell line, Ras pool corresponds to the LP8-3 cell
line, and Ras clone corresponds to the LP8-3A cell line [22]. The experiment was repeated once with the same result. (b) PI3K activity. Quiescent cells were stimulated with 20 ng/ml PDGF-
BB (­) or left untreated (®) for 5 min. After incubation, cells were processed as described in the Materials and methods section for immunoprecipitation of the PI3K using an anti-P-Tyr antibody,
and the immunoprecipitates assayed for PI3K activity as described by Varticovsky et al. [27]. The results shown are an autoradiograph of the products resolved by TLC and the profile (quantification)
of the bands obtained in an electronic autoradiography system (InstantImager). The cell lines are described above. The experiment was repeated twice using the same and other ras-transformed
cell lines (H-ras) with similar results. (c) Western blot using an anti-MAPK (p42 and p44) antibody. Cells were grown to confluence, serum-starved overnight and then stimulated with the indicated
amounts of PDGF or 30 ng/ml bFGF for 10 min. After stimulation, cells were washed twice with ice-cold TD buffer and lysed with lysis or RIPA buffer. Equivalent amounts of protein (30–40 lg)
were resolved by SDS/PAGE (10% gels), transferred to nitrocellulose and blotted against an anti-MAPK polyclonal antibody capable of recognizing both p42MAPK and p44MAPK. Activation of p42MAPK
and p44MAPK is followed by their shift in electrophoretic mobility. C and Control, represent the control LP8-1 cell line ; R and Ras pool represent the ras-transformed LP8-3 cell line ; Ras clone
represents the ras-transformed LP8-3A cell line. (d) Thymidine incorporation induced by mitogens in ras-transformed cells. Cells were grown to confluence and serum-starved for 24 h in 0±2%
FCS, and then stimulated with the indicated growth factors (10 ng/ml) or 20% FCS and incubated in the presence of [3H]thymidine. Cells were processed as described in the Materials and methods
section for thymidine incorporation. Data represent means³variation for duplicate determinations. The experiment was repeated once with similar results. The cell lines used correspond to normal
NIH 3T3 cells (control), the LP8-3 cell line [Ras (pool)], the LP8-3A clone [Ras (clone 1)] or the H-rasV12 [Ras (clone 2)]. +, Quiescent ; 8, PDGF-BB ; 7, bFGF.
formed cells. In contrast, in cells transformed by v-src, c-sis or v-
met, which showed either moderate or very high transforming
activity, PDBu treatment activated PLD to an extent similar to
that found for the ras-transformed cells. Thus no general
correlation of the aggressiveness of each cell line to the synergistic
effect of PDBu on PLD activation was observed. Therefore the
synergistic PLD stimulation is not a result of non-specific effects
of transformation, but seems rather to be specific for the signal-
transduction mechanisms involved for each oncogene.
We also investigated whether the attenuation of PLD stimu-
lation in response to PDGF treatment was a consequence of
unspecific cell transformation. As shown in Table 5, cells
transformed by TGFa, c-sis or v-fgr responded to PDGF
treatment with a similar level of PLD activation to control
untransformed cells, an indication that there was no attenuation
of the PDGF response. In contrast, cells transformed by the v-
met or v-src oncogenes showed a similar attenuation to that
observed in the ras-transformed cells.
Finally, in order to analysis whether there was any correlation
between attenuation of PDGF-induced PLD activation and
uncoupling of the activation of the PI-PLC enzyme in response
to PDGF treatment, we determined IP generation after PDGF
treatment in different oncogene-transformed cells as a measure
of the PI-specific PLC enzyme. As shown in Figure 5, trans-
formation by TGFa or v-fgr with either weak or high trans-
forming activity in the soft-agar assay had no effect on PI-PLC
activation by PDGF. Transformation by c-sis showed a dramatic
but not complete reduction. However, transformation by v-met,
ras and v-src, which showed very high transforming activity in
the soft-agar assay, completely abrogated the effect. These results
indicate that, although there was not a perfect correlation
between attenuated PLD response to PDGF and cell trans-
formation, in all the cases where dramatic uncoupling of the PI-
PLC activation by PDGF treatment was observed, it was
accompanied by PLD attenuation in response to PDGF treat-
ment. These results suggest that attenuation of the PLD response
may be due to uncoupling of the activation of PI-PLC by PDGF
treatment.
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Figure 4 Effects of ras transformation on PDGF-, FGF- and serum-induced
PI-PLC activation
Cells were grown and labelled with [3H]inositol as described. Labelling medium was discarded,
and cells were washed with TD buffer and preincubated with serum-free DMEM supplemented
with 22 mM LiCl for 20 min. They were then stimulated with growth factors (20 ng/ml) or 20%
FCS in the presence of 22 mM LiCl for 30 min. Cells were processed for IP determination as
described in the Materials and methods section. Data represent means³variation for duplicate
determinations. The experiment was repeated once with similar results. Cell lines correspond
to normal NIH 3T3 cells (Control) and the LP8-3 cell line (Ras) as previously described [22].
Table 3 PI-PLC activation in ras transformed cell lines
Cells were grown and labelled with [3H]inositol as described in the Materials and methods
section. Labelling medium was discarded, cells were washed with TD buffer and preincubated
with serum-free DMEM supplemented with 22 mM LiCl for 20 min. Then the cells were
stimulated with 20 ng/ml PDGF in the presence of 22 mM LiCl for 30 min. Cells were
processed for IP determination as described in the Materials and methods section. Data are
means³range for duplicate determinations. Fold increase is the ratio between the data in PDGF
column and the data in Basal column.
IP/total lipid
Fold
Expt. no. Cell line Gene Basal PDGF increase
1 LP8-1 None 5±89³0±14 37±40³1±28 6±34
LP8-3 H-ras V12 4±80³0±07 5±61³0±04 1±16
2 LP14-7 None 3±65³0±10 17±31³0±45 4±74
LP14-8 H-ras R12T59 2±62³0±11 3±82³0±14 1±45
3 LP14-7 None 3±28³0±19 8±29³2±18 2±52
LP14-8 H-ras R12T59 3±09³0±53 3±59³0±23 1±16
DISCUSSION
Alteration of signal-transduction mechanisms at diverse steps
between the membrane and the nucleus is the major target for
cell transformation and the acquisition of oncogenic potential.
Signal transduction is critical for communication between cells
and the regulation of cell growth, differentiation and apoptosis,
the three major events which, if altered, can lead to the generation
of transformed cells. A large number of components involved in
the regulation of such transduction pathways have been charac-
terized since the discovery of the first human oncogene. However,
we may be far from uncovering all the relevant components for
the regulation of these biological processes. Indeed, it is now
generally accepted that cross-talk between different signalling
pathways is a common phenomenon frequently observed in cell
regulation.
Cancer cells are the result of an accumulation of genome
alterations [31]. At least two events, competence and promotion,
are required [32]. Although most oncogenes are thought to be
potent initiators of this process, phorbol esters, which directly
Table 4 Synergism in PLD activation by PDBu in different oncogene-
transformed cells
Cells were grown and labelled in DMEM supplemented with 10% newborn calf serum and
1 lCi/ml [14C]glycerol for 48 h. PLD activation was analysed as indicated in the Materials and
methods section after 45 min of incubation in serum-free DMEM supplemented with 0±5%
butan-1-ol, in the presence or absence of 350 nM PDBu. Quantification was performed by an
electronic autoradiography system. Fold increase represents the increase in PLD activity in the
PDBu-treated cells over that in untreated control cells. Data shown are the means³S.D.
obtained from four independent experiments (each one carried out in duplicate). The relative
number and size of colonies grown in soft agar quantified after 3 weeks of plating as described
in the Materials and methods section are shown. (®), No colonies.
Cell line Gene Colonies
Fold increase
caused by
PDBu
NIH 3T3 None – 4±57³1±09
611-20 TGFa ­ 5±31³2±00
C51-36 trk ­­ 6±30³1±25
704-42 c-sis ­­ 8±84³1±92*
C26-41 v-fgr ­­­ 6±15³1±95
C51-64 v-fms ­­­ 6±02³1±85
12b v-met ­­­­ 12±03³1±87*
LP8-3 H-ras V12 ­­­­ 9±39³2±61*
SRC v-src ­­­­ 10±14³3±18*
* Significantly different from control NIH 3T3 cells, P % 0±05 (Student’s t test).
activate PKC, are among the most potent tumour promoters
known [32]. A similar scenario is seen in normal cell proliferation,
since both competence and progression factors are required for
full mitogenic response [33]. Both competence and progression
factors use signalling pathways that complement each other for
full mitogenic stimulation. One such pathway frequently used in
cell growth induction involves the mobilization of lipid-derived
second messengers [34].
Oncogenes such as src and ras are capable of inducing the
constitutive activation of PLD, an enzyme that is also activated
by stimulation with growth factors in normal cells [6,22,23,35].
There is a functional connection between growth factors, PKC
Table 5 Attenuation of PLD activation induced by PDGF in different
oncogene-transformed cells
Cells were grown and labelled as indicated in the legend to Table 4. PLD activation was analysed
as indicated in Table 4 after 30 min incubation in the presence of 20 ng/ml PDGF.
Cell line Gene NIH 3T3* Oncogenes
Decrease
(%) n
611-20 TGFa 2±58³0±57 2±17³0±63 16 5
704-42 c-sis 2±82³0±36 2±51³0±31 11 3
C26-41 v-fgr 2±58³0±57 2±80³0±89 ®9 5
12b v-met 2±55³0±61 1±57³0±37 38 4
LP8-3 H-rasV12 2±20³0±65 1±32³0±18 40 7
SRC v-src 2±37³0±67 1±26³0±46 47 5
* Represents the ratio between the PDGF-treated cells and the untreated control cells. This
column represents the values obtained for the control cell line (NIH 3T3 cells) as mean³S.D.
for the indicated number of determinations.
 This column represents the fold induction in PLD activity in the different oncogene-
transformed cells after treatment with PDGF over unstimulated control cells. Data correspond
to means³S.D. for the number of independent experiments (each one performed in duplicate)
indicated.
 Significantly different from the results obtained in control NIH 3T3 cells, P % 0±05
(Student’s t test).
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Figure 5 Effect of transformation by different oncogenes on PI-PLC
activation induced by PDGF
Cells were grown and labelled with [3H]inositol as described in the Materials and methods
section. Labelling medium was discarded, and cells were washed with TD buffer and then
preincubated with serum-free DMEM supplemented with 22 mM LiCl for 20 min. They were
then stimulated with 20 ng/ml PDGF in the presence of 22 mM LiCl for 30 min. Cells were
processed for IP determination as described in the Materials and methods section. Data
represent mean³S.D. for three independent experiments each one performed in duplicate. The
control cell line was normal NIH 3T3 cells. Transformed cells were those described in Tables
4 and 5.
and PLD activation, since inhibition of PKC abrogates the PLD
activation in response to growth factors ([9] ; this report).
Moreover, direct activation of PKC by phorbol esters induces a
large and transient increase in PLD activity [1,36], consistent
with the direct involvement of PKC in PLD regulation. In
agreement with previous publications using PDGF receptor
mutants [13], we report here that this activation is probably
mediated through the generation of PI-PLC-derived metabolites
which ends in the activation of PKC. This mechanism would also
provide a common pathway for the effects observed in both
growth factor stimulation with tyrosine kinase receptors and
those related to G-protein-coupled receptors by activation of the
PI-PLCc or PI-PLCb isoenzymes respectively. However, we also
show here that PDBu and growth factors have an additive effect
on PLD activation, since simultaneous stimulation of NIH 3T3
cells with saturating concentrations of both PDGF and PDBu
gives rise to a PLD activation equivalent to the addition of either
one of the stimuli alone. Since all reactive PKC must be activated
by the concentrations of PDBu used, growth factors must affect
PLD by a different mechanism from that of generation of DAG
and PKC activation. Thus, although PKC is necessary for the
activation of PLD by growth factors, it may not be sufficient for
complete PLD activation. Also, it can be concluded that growth
factors require the simultaneous induction of a PKC-dependent
and a PKC-independent mechanism for complete activation of
PLD.
We have further studied whether activation of PLD by growth
factors and oncogenes follow similar pathways. To this end, we
investigated whether the direct activation of PKC by phorbol
esters or mitogenic stimulation by growth factors in the ras-
transformed cells affected PLD activity. Our previous results
demonstrate that ras utilizes a PKC-independent mechanism for
constitutive PLD activation [22]. These results are in keeping
with those published by Song and Foster for src-transformed
cells, demonstrating that activation of PLD by src is PKC-
independent [35]. Ras proteins have been suggested to mediate
the activation of PLD by src [25]. Therefore activation of PLD
by ras should also be PKC-independent, as we have demonstrated
[22]. Unexpectedly, we found that PDBu treatment and ras
transformation have a synergistic effect on PLD activation, the
increase in PLD activity by PDBu treatment being much higher
in ras-transformed cells than in the parental cells under the same
conditions. We demonstrate that this effect is also observed for
the src oncogene, as expected from previous studies where PLD
activation induced by src was proposed to be mediated by the
Ras proteins [25]. In an effort to uncover the mechanism involved
in this synergism, we observed that PKC levels (detected by
Western blot using a monoclonal antibody specific for PKCa}b)
were increased in the ras-transformed cells (results not shown) in
agreement with previous reports [37,38]. However, this does not
seem to be the likely explanation, as the same effect was not
observed in either src- [38] or met-transformed cells, whereas
both these cell lines exhibited strong synergism with phorbol
esters in PLD activation.
In contrast with our observations, a previous report by Martin
et al. [39] showed that in rat 2 fibroblasts transformed by ras, the
PLD response to treatment with phorbol esters was attenuated.
However, consistent with our findings, the constitutive basal
levels of PLD activity were elevated by 100% in the ras-
transformed cells. Besides the different cell lines used in the two
studies, Martin et al. used [$H]myristate for PLD determination,
whereas we used ["%C]glycerol, a precursor that will report all
putative PLD isoenzymes, rather than the specific PLD that uses
myristate-containing phosphatidylcholine as the preferred sub-
strate. This is an important technical difference, which would
explain the results observed, and has been previously demon-
strated to be the correct explanation for src-transformed cells
[23].
In keeping with our observations, other authors have demon-
strated that GTP[S] synergizes with phorbol esters in PLD
activation [40,41], indicating that a GTPase is involved in this
activation, which mimics the effects observed in the ras-
transformed cells. Both Rho and ARF, two members of the
monomeric superfamily of GTPases, have been reported to
activate PLD [15,17]. Furthermore, the two proteins act
synergistically in the activation of rat brain PLD [42], suggesting
the existence of alternative pathways for the activation of PLD.
Finally, it has been recently reported [21] that activation of PLD
in ras-transformed NIH 3T3 cells is mediated by GTP loading of
Ral through activation of Ral-GDS. This finding is consistent
with our results, and suggests that more than one PLD isoenzyme
may exist, each being regulated by specific mechanisms. The fact
that the ras-mediated co-operative activation of PLD by phorbol
esters is dependent on a phorbol-ester-sensitive PKC isoenzyme
indicates that the effect observed involves a functional PKC of
the classical or novel type, which is responsive to DAG and
phorbol esters [43]. This therefore excluded the atypical PKC
isoenzymes (i}k and f ), which are not sensitive to phorbol ester
activation [43].
Unlike the PLD activation induced by PDBu, activation of
PLD by growth factors was significantly attenuated in ras-
transformed cells. This effect was not mediated by non-specific
impairment of PDGF signalling pathways, as other receptor
functions were not uncoupled in the ras-transformed cells. In
contrast, PI-derived metabolites were not generated in response
to serum, bFGF or PDGF-BB in the ras-transformed cells, an
indication that the PI-specific PLC response was completely
abrogated. These results support the hypothesis that activation
of PLD by growth factors is mediated by PKC through the
generation of PI-PLC-derived metabolites. In contrast with these
results, Alam et al. [44] have reported that, in a Kirsten-ras-
transformed cell line, DT, the lack of response of PI-PLC
activation by PDGF was associated with the loss of the PDGF
receptor. However, the authors only tested a single ras clone, in
contrast with our study which uses both mass cultures and
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isolated clones, with similar results. Also, Vaziri and Faller [45]
have recently reported a decreased number of PDGF receptors in
the surface of Kirsten-ras- and src-transformed Balb}c-3T3 cells.
Although we have not determined the actual levels of PDGF
receptor in our Harvey-ras-transformed cells, the fact that we
observed similar levels of receptor autophosphorylation, and
PI3K and MAPK activation after PDGF and FGF treatment
suggests that a decrease in the levels of PDGF receptors is not a
sufficient explanation for the complete abrogation of the PI-PLC
response. Furthermore, we have also observed the same PI-PLC
effect when using PDGF, FGF or serum, which strongly supports
the existence of an alternative explanation. Thus our results
suggest that the attenuation of PLD activation in ras-transformed
cells is probably a consequence of the specific uncoupling of PI-
PLC activation by a still unknown mechanism, preventing gen-
eration of the second messengers, DAG and Ca#+, required for
PKC regulation and subsequent PLD activation.
To investigate whether the effects observed on PLD activation
were a consequence of non-specific events caused by cell trans-
formation, we studied the activation of PLD by PDBu and
PDGF treatment in several transformed cell lines. A complete
range of weak to very highly transformed cells was selected to
study the putative correlation between PLD activation and
tumorigenicity. The results indicate that there is no general
correlation between transformation and synergism or attenuation
of PLD response to PDBu and growth factors respectively.
Different situations were found among the different oncogene-
transformed cells such as synergism with PDBu and attenuation
of PDGF treatment (ras, src, met), co-operation with PDBu but
no attenuation of PDGF (sis), and no co-operation and no
attenuation (TGFa, fgr). These results indicate that activation of
PLD by oncogenes is specific and depends on the particular
pathway activated in each case. Besides the involvement of PLD
in signalling by growth factors and oncogenes, it can also be
concluded that PLD activation is a redundant or non-essential
effect which may be dispensable for cell proliferation and
transformation. This important conclusion is also based on the
finding that abrogation of PLD activation by growth factors,
accomplished by either PKC down-regulation or direct inhi-
bition, does not affect DNA synthesis in response to growth
factors ([45a] ; this report). A similar situation has been described
for other signalling molecules activated after growth stimulation
such as PI-PLC [46,47], PI3K [47] and MAPK [48]. However, it
is important to realize that the most highly transforming cell lines
analysed consistently showed both effects, synergism with PDBu
and attenuation of PLD activation by growth factors. Whether
these events are functionally related requires further investi-
gation.
Thus PLD activity is synergisticaly enhanced in some of the
oncogene-transformed cells in reponse to PKC activation, and it
is dramatically impaired in response to growth factor stimulation.
This attenuation is, in most cases investigated, paralleled by
complete uncoupling of the PI-PLC pathway. We have further
demonstrated the existence of at least two alternative
mechanisms, PKC-dependent and PKC-independent, for the
activation of PLD, and provide evidence that suggests the
involvement of Ras proteins in the regulation of PLD. Although
we do not yet have a complete understanding of the mechanism
involved, this effect could be a result of the interaction of the Ras
protein with the PLD enzyme and its translocation to the
appropriate membrane environment. Once in the membrane, it
may be accessible to full activation by PKC. This model is similar
to that of the Raf-1 kinase, which becomes translocated to the
membrane by association with Ras proteins, where it is further
activated by either direct phosphorylation [49–52] or by inter-
action with other proteins such as the 14-3-3 proteins, by still
unresolved mechanisms [53–57]. Consistent with our findings, a
recent report indicates that Ras proteins can activate PLD
through Ral-GDS, the exchange factor of Ral, another GTPase
of the Ras superfamily [21]. Other oncogenes also affect the
activation of the PLD enzyme in a similar way to ras. Although
we have not determined whether this effect depends on ras, this
is a possibility that deserves further investigation. Finally, we
show that activation of PLD by growth factors is more complex
than expected, requiring molecules other than those involved in
the PI-PLC}PKC pathway. All the results presented strongly
indicate that PLD is an important molecule in signal transduction
and may be involved in signalling in cell transformation induced
by several oncogenes.
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